Press Release

High Potency Probiotic Sivomixx®800 Reduces Chronic Fatigue in Patients Following Covid Hospitalization

Lausanne, January 12, 2022 — A new clinical study further supports the application of targeted probiotics in the war on Covid-19.

Ormendes SA (Lausanne) announced today the results of a clinical study conducted with its probiotic formulation Slab51 (Sivomixx®800) published in Frontiers in Nutrition (1). The administration of Sivomixx®800 during hospitalisation for COVID-19 prevented the development of chronic fatigue. Fatigue can linger for several months after Covid-19, leaving people feeling dull and finding it difficult to concentrate and recall memories. Sivomixx®800 was administered in a high dose of 2,400 billion bacteria daily to twenty-four COVID-19 patients for their entire hospital stay (median 23 days) in addition to the usual standard of care. Another group of thirty-four COVID-19 patients received only standard of care for comparison purposes.

Six months after discharge from the hospital, the doctors at the Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy registered a significantly lower proportion of subjects positive for fatigue in patients supplemented with Sivomixx®800, compared to those on standard care only (41.7% (10/24) vs. 91% (31/34); p<0.01). Metabolomic testing confirmed better glucose and energy pathways utilization in the Sivomixx800 treated patients.

“The long term effects of post-COVID fatigue are currently under reported and poorly understood against the wider backdrop of the global pandemic”, said Dr Ceccarelli. “This new study on the Slab51 probiotic blend is potentially groundbreaking in that it suggests that a certain probiotic combination could be a promising therapeutic option for preventing the long-term fatigue that often follows a covid hospitalization.”

Previous studies have reported the benefits of Sivomixx®800 for COVID‑19 patients during the hospital stay (2-6). These additional findings support the adjuvant treatment with Sivomixx®800 to improve metabolic homeostasis and reduce chronic symptoms correlated to the central nervous system after hospital discharge.

The authors concluded that administration of the Sivomixx®800 probiotic formula during hospitalisation positively affects the subject’s performance months later.

SivoMixx®800

SivoMixx®800 is a food supplement containing different strains of lactic acid bacteria and bifidobacteria at a concentration of 800 billion CFU (Colony Forming Units) per sachet. It is not intended to treat, prevent, or cure any disease.

More information at www.sivomixx800.com

About Ormendes

Ormendes is a biotechnology company focused on the development and commercialization of live biotherapeutic medicines (www.ormendes.ch). Sivomixx®800 is a probiotic food supplement (www.sivomixx800.com)

References

  1. Santinelli L, Laghi L, Innocenti GP, Claudia P, Vassalini P, Celani L, Lazzaro A, Borrazzo C, Marazzato M, Tarsitani L, Koukopoulos AE, Mastroianni C, d’Ettorre G and Ceccarelli G (2021) Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients. Front. Nutr. 8:756177. doi: 10.3389/fnut.2021.756177
  2. Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti GP, Cavallari EN, et al. Oral bacteriotherapy in patients with COVID-19: a retrospective cohort study. Front Nutr. (2021) 7:613928. doi: 10.3389/fnut.2020.613928
  3. Ceccarelli G, Scagnolari C, Pugliese F, Mastroianni CM, d’Ettorre G. Probiotics and COVID-19. Lancet Gastroenterol Hepatol. (2020) 5:721–2. doi: 10.1016/S2468-1253(20)30196-5
  4. d’Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al. Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med. (2020) 7:389. doi: 10.3389/fmed.2020.00389
  5. Araimo F, Imperiale C, Tordiglione P, Ceccarelli G, Borrazzo C, Alessandri F, et al. Ozone as adjuvant support in the treatment of COVID-19: a preliminary report of probiozovid trial. J Med Virol. (2021) 93:2210–20. doi: 10.1002/jmv.26636
  6. Marazzato M, Ceccarelli G, d’Ettorre G. Dysbiosis in SARS-CoV-2-infected patients. Gastroenterology. (2021) 160:2195. doi: 10.1053/j.gastro.2020.12.056

Press contact

Florence Pryen, Managing Director
+41 (0)79 640 75 20
f.pryen@ormendes.ch

More about Sivomixx® 800

Visit website